ATAI Life Sciences NV Cash Flow-to-Debt Ratio
ATAI Life Sciences NV cash flow-to-debt ratio. ATAI Life Sciences NV (9VC) has a Cash Flow-to-Debt Ratio of -0.29x as of September 2025, meaning its operating cash flow of €-23.26 Million could theoretically repay 0% of its total liabilities (€79.91 Million) in one year. Check ATAI Life Sciences NV cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of ATAI Life Sciences NV (2019–2024)
Cash flow-to-debt ratio of ATAI Life Sciences NV from 2019 to 2024. Historical debt coverage capacity for ATAI Life Sciences NV across 6 annual periods. Also explore 9VC shareholders equity momentum to track the company's year-over-year net asset growth rate.
ATAI Life Sciences NV Cash Flow-to-Debt Ratio by Year (2019–2024)
ATAI Life Sciences NV cash flow-to-debt ratio by year from 2019 to 2024. Year-by-year debt coverage analysis for ATAI Life Sciences NV. For the full cash flow conversion analysis, see ATAI Life Sciences NV operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.92x | €-82.44 Million | €42.83 Million | ▼ -12.5% |
| 2023 | -1.71x | €-84.12 Million | €49.16 Million | ▲ +35.0% |
| 2022 | -2.63x | €-104.47 Million | €39.67 Million | ▼ -17.4% |
| 2021 | -2.24x | €-63.25 Million | €28.21 Million | ▼ -74.7% |
| 2020 | -1.28x | €-20.77 Million | €16.18 Million | ▲ +59.5% |
| 2019 | -3.17x | €-7.85 Million | €2.48 Million | — |